Literature DB >> 23605565

ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.

Hyojin Kim, Eunhyang Park, Yu Jung Kim, Jin-Haeng Chung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23605565     DOI： 10.1007/s00428-013-1413-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  4 in total

Review 1.  Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.

Authors:  Pablo Perez-Moreno; Elisabeth Brambilla; Roman Thomas; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

2.  ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

Authors:  Jamie E Chaft; Natasha Rekhtman; Marc Ladanyi; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

3.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

Authors:  She-Juan An; Zhi-Hong Chen; Jian Su; Xu-Chao Zhang; Wen-Zhao Zhong; Jin-Ji Yang; Qing Zhou; Xue-Ning Yang; Ling Huang; Ji-Lin Guan; Qiang Nie; Hong-Hong Yan; Tony S Mok; Yi-Long Wu
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240
  4 in total
  7 in total

Review 1.  Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.

Authors:  Hyojin Kim; Jin-Haeng Chung
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets.

Authors:  Mercedes L Dalurzo; Alejandro Avilés-Salas; Fernando Augusto Soares; Yingyong Hou; Yuan Li; Anna Stroganova; Büge Öz; Arif Abdillah; Hui Wan; Yoon-La Choi
Journal:  Onco Targets Ther       Date:  2021-09-01       Impact factor: 4.345

3.  Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases.

Authors:  Anna Scattone; Annamaria Catino; Laura Schirosi; Lucia Caldarola; Stefania Tommasi; Rosanna Lacalamita; Elisabetta Sara Montagna; Domenico Galetta; Gabriella Serio; Francesco Alfredo Zito; Anita Mangia
Journal:  Transl Oncol       Date:  2018-12-04       Impact factor: 4.243

Review 4.  Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.

Authors:  Paul Hofman
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

5.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Qiyi Meng; Yujie Dong; Hong Tao; Liang Shi; Li Tong; Junfang Tang; Shucai Zhang; Zhe Liu
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

Review 6.  Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.

Authors:  Hyojin Kim; Hyo Sup Shim; Lucia Kim; Tae-Jung Kim; Kun Young Kwon; Geon Kook Lee; Jin-Haeng Chung
Journal:  Korean J Pathol       Date:  2014-02-25

7.  Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report.

Authors:  Wenxian Wang; Zhengbo Song; Yiping Zhang
Journal:  Thorac Cancer       Date:  2015-07-29       Impact factor: 3.500
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.